Our Mission
ImmuNovX Biotech is an early-stage company whose mission is to develop the groundbreaking technology
we call LR3N-CS, a platform that allows rapid,
large-scale treatment of DNA pathogens to
generate a novel class of vaccines.
Our Science
The LR3N-CS platform technology chemically binds the DNA of treated pathogens via a cell-free manufacturing process, resulting in live-attenuated, replication-defective DNA pathogens. The system significantly reduces the time
required to develop, manufacture, and deploy
DNA pathogen vaccines, at a fraction of the cost
of currently-available processes
--enabling a novel class of DNA vaccines.
Partnering
ImmuNovX is actively seeking partners, and would value the opportunity to discuss potential synergies.